• Guidelines:

    1. There is a maximum of 3 image uploads allowed. The only accepted file formats are JPG, JPEG, PNG, and GIF. There are four sections: Background, Methods Results, and Conclusions. You are allowed a TOTAL of 1,900 characters for all four sections combined. Please note that each image counts as 500 characters.
    1. Abstracts that have been previously published or presented will NOT be eligible for presentation at SCAI. If your abstract is accepted for presentation at another meeting or published prior to the SCAI 2019 Scientific Sessions you must notify SCAI immediately to withdraw your abstract.
    1. Case Studies will NOT be accepted or considered for presentation at the SCAI 2019 Scientific Sessions.
    1. Investigators should not submit the same research; applications that appear to be replicate versions of a single study will be rejected.
    1. The SCAI Program Committees endorse the position of the American Association for the Advancement for Science in requiring assurances of the responsible use of animals in research. All submissions for consideration must be in compliance with the guidelines.
    1. Abstract submissions must fit into one of the following categories: 

    • Acute Coronary Syndromes, Myocardial Infarction, Thrombectomy, and Vulnerable Plaque 
    • Adult Congenital 
    • Angiogenesis, Myogenesis, Cell Therapy, and Gene Therapy 
    • Complex PCI, Restenosis, Left Main, and Multi-Vessel Intervention 
    • Contrast Agents 
    • Endovascular and Peripheral Interventions (including Neurovascular and Carotid)
    • Imaging: CT, MR, and Non-Invasive Imaging 
    • Intravascular Imaging (IVUS/OCT/NIR/Other) and Physiology (FFR/iFR/IMR/other)
    • Miscellaneous 
    • Pediatric 
    • Pharmacotherapy 
    • Quality Improvement 
    • Stents (including DES) 
    • Valvular Interventions and Structural Heart Disease 
    • Vascular Access and Arterial Closure Devices

    1. Each presenting author will be asked to comply with the SCAI Disclosure Policy. Indication of the relationship, the associated commercial entity, and level of support is required for each presenting author. All presenters at SCAI's Annual Scientific Sessions must display a slide at the beginning of their presentation indicating disclosure information as applicable, or that they have nothing to disclose.
    1. All revisions must be made by the abstract submission deadline.

    The submitter acts on behalf of all co-authors and in submitting an abstract/late-breaking clinical science, transfers to SCAI the copyright and all other rights in the material comprising the application if the application is accepted. Co-authors reserve the following:

    • All proprietary rights other than copyright, such as patent rights; and

    • The right to use all or part of the application in future works of their own. The meeting organizers, as holder of the copyright on the accepted application, reserve all rights of reproduction, distribution, performance, display, and the right to create derivative works in both print and digital formats.

    1. Abstract acceptance notifications will be e-mailed to the addresses provided for the presenting authors in early February along with presentation guidelines. 
    1. Any abstract presenting data that in whole or part is contained in a Late-Breaking Clinical Science submission that was accepted to be presented in the SCAI Annual Scientific Sessions general abstract program cannot be presented in the regular program and must be withdrawn if that trial is accepted for presentation as a Late-Breaking Clinical Science presentation. 
    1. Requests to withdraw an abstract must be submitted in writing to meetings@scai.org by February 6, 2019. 
    1. SCAI promotes Abstracts, Late-Breaking Clinical Science, research, and presentations to online, print, and broadcast media on behalf of SCAI 2019 Scientific Sessions. 
    1. Embargoed Content: All authors, presenters, company sponsors, attendees, journalists and/or anyone with knowledge of embargoed content must comply with SCAI embargo policies, which state that scientific study results presented during the Annual Scientific Sessions must not be released publicly prior to the time of presentation at the Annual Scientific Sessions or the SCAI-sponsored press conference, whichever comes first. In the event that the media contacts authors directly, authors, presenters and/or company sponsors must first seek SCAI approval for information to be shared with the understanding that it is under embargo. Responsibility for information shared in this manner rests solely with the disclosing authors, presenters and/or company sponsors. The SCAI leadership, press staff, and meeting co-chairs will be available to work with the disclosing party to develop an acceptable release of the required information if specific disclosures (e.g., SEC requirements) must be met or in the case of public health concern.  The embargo on poster presentations lifts when the poster session containing the poster opens for viewing. The only exception to the above-mentioned embargo rules are closed investigator meetings for participants in the trial. The Annual Scientific Sessions Committees may ask you to supply investigator meeting date/time/location information if your submission is accepted.

      

    Questions? Please contact SCAI Senior Meetings Manager Rachel Pham at rpham@scai.org or 202.741.9960.